baricitinib AD
Selected indexed studies
- Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). (Br J Dermatol, 2023) [PMID:36999560]
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (J Allergy Clin Immunol, 2023) [PMID:37678577]
- JAK inhibitors in the treatment of atopic dermatitis. (J Allergy Clin Immunol, 2021) [PMID:34437922]
_Worker-drafted node — pending editorial review._
Connections
baricitinib AD is a side effect of
Sources
- Baricitinib Withdrawal and Retreatment in Patients With Severe Alopecia Areata: The BRAVE-AA1 Randomized Clinical Trial. (2024) pubmed
- Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. (2023) pubmed
- JAK inhibitors in the treatment of atopic dermatitis. (2021) pubmed
- Guidelines of care for the management of atopic dermatitis in adults with phototherapy and systemic therapies. (2024) pubmed
- Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). (2023) pubmed
- Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs. (2024) pubmed
- Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. (2022) pubmed
- Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. (2020) pubmed
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial. (2020) pubmed
- Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis. (2022) pubmed